65. Coste J., Billionnet C., Rudnichi A. et al. Statins for primary prevention and rhabdomyolysis: A nationwide cohort study in France. Eur J Prev Cardiol. 2019 Mar;26(5):512–521. doi: 10.11 77/2047487318776831. www.ncbi.nlm.nih.gov/ pubmed/29799296 (дата обращения: 31.01.2021).
66. Toussirot E., Michel F., Meneveau N. Rhabdomyolysis Occurring under Statins after Intense Physical Activity in a Marathon Runner. Case Rep Rheumatol. 2015;2015:721078. doi: 10.1155/2015/721078. www.ncbi.nlm.nih.gov/pubmed/25815236 (дата обращения: 31.01.2021).
67. Ward F.L., John R, Bargman J.M., McQuillan R.F. Renal Tubular Toxicity Associated With Rosuvastatin Therapy. Am J Kidney Dis. 2017 Mar;69(3):473–476. doi: 10.1053/j.ajkd.2016.08.037. www.ncbi.nlm.nih.gov/pubmed/27856086 (дата обращения: 31.01.2021).
68. Zhang H., Cui Y., Zhao Y. et al. Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertens Res. 2019 May;42(5):717–729. doi: 10.1038/s41440-018-0165-7. www.ncbi.nlm.nih.gov/ pubmed/30552406 (дата обращения: 31.01.2021).
69. Bosch J., O’Donnell M., Swaminathan B. et al. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. Neurology. 2019 Mar 26;92(13):e1435-e1446. doi: 10.1212/WNL.0000000000007174. www.ncbi.nlm.nih. gov/pubmed/30814321 (дата обращения: 31.01.2021).
70. Rech R.L., de Lima M.N., Dornelles A. et al. Reversal of age-associated memory impairment by rosuvastatin in rats. Exp Gerontol. 2010 May;45(5):351-6. doi: 10.1016/j. exger.2010.02.001. www.ncbi.nlm.nih.gov/pubmed/20138979 (дата обращения: 31.01.2021).
71. Rojas-Fernandez C.H., Cameron J.C. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012 Apr;46(4):549-57. doi: 10.1345/aph.1Q620. www.ncbi.nlm.nih. gov/pubmed/22474137 (дата обращения: 31.01.2021).
72. Chen Z., Qureshi A.R., Parini P. et al. Does statins promote vascular calcification in chronic kidney disease? Eur J Clin Invest. 2017 Feb;47(2):137–148. doi: 10.1111/eci.12718. www.ncbi.nlm.nih.gov/pubmed/28036114 (дата обращения: 31.01.2021).
73. Berkner K.L., Runge K.W. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost. 2004 Dec;2(12):2118-32. doi: 10.1111/j.1538–7836.2004.00968.x. www.ncbi.nlm.nih.gov/ pubmed/15613016 (дата обращения: 31.01.2021).
74. Price P.A. Role of vitamin-K-dependent proteins in bone metabolism. Annu Rev Nutr. 1988;8:565-83. doi: 10.1146/annurev.nu.08.070188.003025. www.ncbi.nlm.nih. gov/pubmed/3060178 (дата обращения: 31.01.2021).
75. Knapen M.H., Braam L.A., Drummen N.E. et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. Thromb Haemost. 2015 May;113(5):1135-44. doi: 10.1160/TH14-08-0675. www.ncbi.nlm.nih.gov/pubmed/25694037 (дата обращения: 31.01.2021).
76. Richaud J., Bousquet P., Ealet G. et al. [Recalibration via a postero-lateral approach in recent traumatic stenosis of the dorsal and lumbar spine. Modalities and results apropos of 31 cases]. Neurochirurgie. 1990;36(1):27–38. [Article in French] www.ncbi.nlm.nih.gov/pubmed/2352589 (дата обращения: 31.01.2021).
77. Huang Z.B., Wan S.L., Lu Y.J. et al. Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials. Osteoporos Int. 2015 Mar;26(3):1175-86. doi: 10.1007/s00198-014-2989-6. www.ncbi.nlm.nih.gov/pubmed/25516361 (дата обращения: 31.01.2021).
78. Lin T.K., Liou Y.S., Lin C.H. et al. High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. Clin Epidemiol. 2018 Jan 18;10:159–165. doi: 10.2147/CLEP.S145311. www.ncbi.nlm.nih.gov/pubmed/29403315 (дата обращения: 31.01.2021).
79. Anyanwagu U., Mamza J., Donnelly R., Idris I. Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study. Cardiovasc Diabetol. 2017 Aug 22;16(1):107. doi: 10.1186/s12933-017-0587-6. www.ncbi.nlm.nih.gov/pubmed/28830436 (дата обращения: 31.01.2021).
80. Cai X., Tian Y., Wu T. et al. The role of statins in erectile dysfunction: a systematic review and meta-analysis. Asian J Androl. May-Jun 2014;16(3):461-6. doi: 10.4103/1008-682X.123678. www.ncbi.nlm.nih.gov/pubmed/24556747 (дата обращения: 31.01.2021).
81. Upala S., Wirunsawanya K., Jaruvongvanich V., Sanguankeo A. Effects of statin therapy on arterial stiffness: A systematic review and meta-analysis of randomized controlled trial. Int J Cardiol. 2017 Jan 15;227:338–341. doi: 10.1016/j. ijcard.2016.11.073. www.ncbi.nlm.nih.gov/pubmed/27839806 (дата обращения: 31.01.2021).
82. Folkers K., Langsjoen P., Willis R. et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8931-4. doi: 10.1073/ pnas.87.22.8931. www.ncbi.nlm.nih.gov/pubmed/2247468 (дата обращения: 31.01.2021).
83. Ghirlanda G., Oradei A., Manto A. et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993 Mar;33(3):226-9. doi: 10.1002/j.1552–4604.1993.tb03948.x. www. ncbi.nlm.nih.gov/pubmed/8463436 (дата обращения: 31.01.2021).
84. Mortensen A.L., Rosenfeldt F., Filipiak K.J. Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized doubleblind trial. Cardiol J. 2019;26(2):147–156. doi: 10.5603/CJ.a2019.0022. www.ncbi.nlm. nih.gov/pubmed/30835327 (дата обращения: 31.01.2021).
85. Lee B.J., Tseng Y.F., Yen C.H., Lin P.T. Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial. Nutr J. 2013 Nov 6;12(1):142. doi: 10.1186/1475-2891-12-142. www.ncbi.nlm.nih.gov/pubmed/24192015 (дата обращения: 31.01.2021).
86. Bruikman C.S., Stoekenbroek R.M., Hovingh G.K., Kastelein J.P. New Drugs for Atherosclerosis. Can J Cardiol. 2017 Mar;33(3):350–357. doi: 10.1016/j.cjca.2016.09.010. www.ncbi.nlm.nih.gov/pubmed/27993452 (дата обращения: 31.01.2021).
87. Hegele R.A., Barter P. Дислипидемия и ее лечение. (Электронный ресурс) URL: https://old.medach.pro/wp-content/uploads/2017/01/DLP4.pdf (дата обращения: 31.01.2021).
88. Vrabl k M. Current and future trends in the treatment of dyslipidemias. Vnitr Lek. Winter 2019;65(10):643–650. www.ncbi.nlm.nih.gov/pubmed/31906686 (дата обращения: 31.01.2021).
89. Bonaca MP., Nault P., Giugliano R.P. et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018 Jan 23;137(4):338–350. doi: 10.1161/CIRCULATIONAHA.117.032235. www.ncbi.nlm.nih.gov/pubmed/29133605 (дата обращения: 31.01.2021).
90. Mattson M.P., Maudsley S. Live longer sans the AT1A receptor. Cell Metab. 2009 May;9(5):403-5. doi: 10.1016/j.cmet.2009.04.002. www.ncbi.nlm.nih.gov/ pubmed/19416709 (дата обращения: 31.01.2021).
91. Herbert K.E., Mistry Y., Hastings R. et al. Angiotensin II-mediated oxidative DNA damage accelerates cellular senescence in cultured human vascular smooth muscle cells via telomere-dependent and independent pathways. Circ Res. 2008 Feb 1;102(2):201-8. doi: 10.1161/CIRCRESAHA.107.158626. www.ncbi.nlm.nih.gov/pubmed/17991883 (дата обращения: 2 февраля 2021).
92. Telmisartan. (Электронный ресурс) URL: www.drugs.com/monograph/ telmisartan.html (дата обращения: 2 февраля 2021).
93. Makino H., Haneda M., Babazono T. et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res. 2008 Apr;31(4):657-64. doi: 10.1291/hypres.31.657. www.ncbi.nlm.nih.gov/pubmed/18633177 (дата обращения: 01.02.2021).
94. Frampton J.E. Telmisartan: a review of its use in cardiovascular disease prevention. Drugs. 2011 Apr 16;71(6):651-77. doi: 10.2165/11206710-000000000-00000. www. ncbi.nlm.nih.gov/pubmed/21504246 (дата обращения: 01.02.2021).
95. Volpe M. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers? QJM. 2012 Jan;105(1):11–27. doi: 10.1093/qjmed/hcr190. www.ncbi. nlm.nih.gov/pubmed/22011630 (дата обращения: 01.02.2021).
96. Matsui T., Yamagishi S., Ueda S. et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res. Jul-Aug 2007;35(4):482-9. doi: 10.1177/147323000703500407. www. ncbi.nlm.nih.gov/pubmed/17697525 (дата обращения: 01.02.2021).
97. Linz W., Jessen T., Becker R.H. et al. Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation. 1997 Nov 4;96(9):3164-72. doi: 10.1161/01. cir.96.9.3164. www.ncbi.nlm.nih.gov/pubmed/9386189 (дата обращения: 01.02.2021).
98. Dial S., Nessim S.J., Kezouh A. et al. Antihypertensive agents acting on the reninangiotensin system and the risk of sepsis. Br J Clin Pharmacol. 2014 Nov;78(5):1151-8. doi: 10.1111/bcp.12419. www.ncbi.nlm.nih.gov/pubmed/24803383 (дата обращения: 01.02.2021).